Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV004950275 | SCV005547399 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2024-08-19 | criteria provided, single submitter | clinical testing | The p.H1686D variant (also known as c.5056C>G), located in coding exon 15 of the BRCA1 gene, results from a C to G substitution at nucleotide position 5056. The histidine at codon 1686 is replaced by aspartic acid, an amino acid with similar properties. One functional study found that this nucleotide substitution is non-functional in a high throughput genome editing haploid cell survival assay (Findlay GM et al. Nature, 2018 Oct;562:217-222). Two other variants at the same codon in the BRCT domain, p.H1686R (c.5057A>G) and p.H1686Q (c.5057A>G), have been identified in affected patients and shown to be non-functional in several assays (Giannini G, et al. J. Clin. Oncol. 2008;26(25):4212-4; Ambry internal data; Bouwman P et al. Cancer Discov. 2013 Oct;3(10):1142-55; Carvalho MA, et al. Cancer Biol Ther. 2002 Sep-Oct;1(5):502-8; Findlay GM et al. Nature, 2018 Oct;562:217-222). This amino acid position is highly conserved in available vertebrate species. This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |
| Brotman Baty Institute, |
RCV001076298 | SCV001242018 | not provided | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion provided | in vitro | ||
| BRCAlab, |
RCV001076298 | SCV004243956 | likely pathogenic | Breast-ovarian cancer, familial, susceptibility to, 1 | 2024-02-02 | no assertion criteria provided | clinical testing |